Skip to main content
Top
Published in: Trials 1/2019

Open Access 01-12-2019 | Care | Research

Development, acceptability, appropriateness and appeal of a cancer clinical trials implementation intervention for rural- and minority-serving urology practices

Authors: Shellie Ellis, Mugur Geana, Tomas Griebling, Charles McWilliams, Jessie Gills, Kelly Stratton, Christine Mackay, Ariel Shifter, Andrew Zganjar, Brantley Thrasher

Published in: Trials | Issue 1/2019

Login to get access

Abstract

Background

Few community urologists offer cancer patients the opportunity to participate in cancer clinical trials, despite national guidelines that recommend it, depriving an estimated 260,000 urological cancer patients of guideline-concordant care each year. Existing strategies to increase urologists’ offer of clinical trials are designed for resource-rich environments and are not feasible for many community urologists. We sought to design an implementation intervention for dissemination in under-resourced community urology practices and to compare its acceptability, appropriateness and adoption appeal among trial-naïve and trial-experienced urologists.

Methods

We used a design-for-dissemination approach, informed by the Theoretical Domains Framework and Behavior Change Wheel, to match determinants of the clinical trial offer to theoretically informed implementation strategies. We described the implementation intervention in evaluation workshops offered at urology professional society meetings. We surveyed participants to assess the implementation intervention’s acceptability and appropriateness using validated instruments. We also measured adoption appeal, intention to adopt and previous trial offer.

Results

Our design process resulted in a multi-modal implementation intervention, comprised of multiple implementation strategies designed to address six domains from the Theoretical Domains Framework. Evaluation workshops delivered at four meetings, convened five separate professional societies. Sixty-one percent of those offered an opportunity to participate in the implementation intervention indicated intention to adopt. Average implementation intervention acceptability and appropriateness ratings were 4.4 and 4.4 (out of 5), respectively. Acceptability scores were statistically significantly higher among those offering trials compared to those not (p = 0.03). Appropriateness scores did not differ between those offering trials and those not (p = 0.24). After urologists ranked their top three innovation attributes, 43% of urologists included practice reputation in their top three reasons for offering clinical trials; 30% listed practice differentiation among their top three reasons. No statistically significant differences were found between those who offered trials and those who did not among any of the innovation attributes.

Conclusions

LEARN|INFORM|RECRUIT is a promising implementation intervention to address low accrual to clinical trials, poised for implementation and effectiveness testing. The implementation intervention is appealing to its target audience and may have equal uptake among trial-naïve and trial-experienced practices.
Appendix
Available only for authorised users
Literature
1.
go back to reference Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book. 2016;35:185–98.CrossRef Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book. 2016;35:185–98.CrossRef
2.
go back to reference American Cancer Society Cancer Action Network. Barriers to patient enrollment in therapeutic clinical trials for cancer: a landscape report. Washington, D.C.: American Cancer Society; 2018. American Cancer Society Cancer Action Network. Barriers to patient enrollment in therapeutic clinical trials for cancer: a landscape report. Washington, D.C.: American Cancer Society; 2018.
3.
go back to reference Korn EL, Freidlin B, Mooney M, Abrams JS. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. J Clin Oncol. 2010;28(35):5197–201.CrossRef Korn EL, Freidlin B, Mooney M, Abrams JS. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. J Clin Oncol. 2010;28(35):5197–201.CrossRef
4.
go back to reference Schroen AT, Petroni GR, Wang H, Thielen MJ, Gray R, Benedetti J, et al. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res. 2012;18(1):256–62.CrossRef Schroen AT, Petroni GR, Wang H, Thielen MJ, Gray R, Benedetti J, et al. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res. 2012;18(1):256–62.CrossRef
5.
go back to reference Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL. Predicting low accrual in the National Cancer Institute’s Cooperative Group Clinical Trials. J Natl Cancer Inst. 2016;108(2):article number djv324.CrossRef Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL. Predicting low accrual in the National Cancer Institute’s Cooperative Group Clinical Trials. J Natl Cancer Inst. 2016;108(2):article number djv324.CrossRef
6.
go back to reference Albrecht TL, Eggly SS, Gleason ME, Harper FW, Foster TS, Peterson AM, et al. Influence of clinical communication on patients’ decision making on participation in clinical trials. J Clin Oncol. 2008;26(16):2666–73.CrossRef Albrecht TL, Eggly SS, Gleason ME, Harper FW, Foster TS, Peterson AM, et al. Influence of clinical communication on patients’ decision making on participation in clinical trials. J Clin Oncol. 2008;26(16):2666–73.CrossRef
7.
go back to reference Moorcraft SY, Marriott C, Peckitt C, Cunningham D, Chau I, Starling N, et al. Patients’ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Trials. 2016;17:17.CrossRef Moorcraft SY, Marriott C, Peckitt C, Cunningham D, Chau I, Starling N, et al. Patients’ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Trials. 2016;17:17.CrossRef
8.
go back to reference Kaplan CP, Napoles AM, Narine S, Gregorich S, Livaudais-Toman J, Nguyen T, et al. Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients. Contemp Clin Trials. 2015;45(Pt B):443–8.CrossRef Kaplan CP, Napoles AM, Narine S, Gregorich S, Livaudais-Toman J, Nguyen T, et al. Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients. Contemp Clin Trials. 2015;45(Pt B):443–8.CrossRef
9.
go back to reference Dimond EP, St Germain D, Nacpil LM, Zaren HA, Swanson SM, Minnick C, et al. Creating a “culture of research” in a community hospital: strategies and tools from the National Cancer Institute Community Cancer Centers Program. Clin Trials. 2015;12(3):246–56.CrossRef Dimond EP, St Germain D, Nacpil LM, Zaren HA, Swanson SM, Minnick C, et al. Creating a “culture of research” in a community hospital: strategies and tools from the National Cancer Institute Community Cancer Centers Program. Clin Trials. 2015;12(3):246–56.CrossRef
10.
go back to reference Institute of Medicine (US) Forum on Drug Discovery Development and Translation. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. The National Academies Collection: Reports funded by National Institutes of Health. Washington (DC): The National Academies of Sciences, Engineering, and Medicine; 2010. Institute of Medicine (US) Forum on Drug Discovery Development and Translation. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. The National Academies Collection: Reports funded by National Institutes of Health. Washington (DC): The National Academies of Sciences, Engineering, and Medicine; 2010.
11.
go back to reference American Society of Clinical Oncology. The state of cancer care in America, 2017: a report by the American Society of Clinical Oncology. J Oncol Pract. 2017;13(4):e353–e94.CrossRef American Society of Clinical Oncology. The state of cancer care in America, 2017: a report by the American Society of Clinical Oncology. J Oncol Pract. 2017;13(4):e353–e94.CrossRef
12.
go back to reference U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2018 submission data (1999–2016). Atlanta: US. Department of Health and Human Services, Center for Disease Control and Prevention and National Cancer Institute; 2017. U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2018 submission data (1999–2016). Atlanta: US. Department of Health and Human Services, Center for Disease Control and Prevention and National Cancer Institute; 2017.
13.
go back to reference Swanson GP, Carpenter WR, Thompson IM, Crawford ED. Urologists’ attitudes regarding cancer clinical research. Urology. 2007;70(1):19–24.CrossRef Swanson GP, Carpenter WR, Thompson IM, Crawford ED. Urologists’ attitudes regarding cancer clinical research. Urology. 2007;70(1):19–24.CrossRef
14.
go back to reference Smelser WW, Holzbeierlein JM. Multidisciplinary care in genitoruinary cancer treatment: an imperative for the care continuum. Alexandria: 2018 Gentiourinary Cancers Symposium; 2018. Smelser WW, Holzbeierlein JM. Multidisciplinary care in genitoruinary cancer treatment: an imperative for the care continuum. Alexandria: 2018 Gentiourinary Cancers Symposium; 2018.
15.
go back to reference Prades J, Remue E, van Hoof E, Borras JM. Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy. 2015;119(4):464–74.CrossRef Prades J, Remue E, van Hoof E, Borras JM. Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy. 2015;119(4):464–74.CrossRef
17.
go back to reference Williams SB, Kamat AM. The multidisciplinary approach to prostate cancer management: from diagnosis and beyond. Everyday Urol Oncol Insights. 2018;2(2):article number 98076. Williams SB, Kamat AM. The multidisciplinary approach to prostate cancer management: from diagnosis and beyond. Everyday Urol Oncol Insights. 2018;2(2):article number 98076.
18.
go back to reference Berger ER, Shore N. Our prostate cancer patients need true multidisciplinary care. Oncol Times. 2005;27(19):4.CrossRef Berger ER, Shore N. Our prostate cancer patients need true multidisciplinary care. Oncol Times. 2005;27(19):4.CrossRef
19.
go back to reference Horvath LE, Yordan E, Malhotra D, Leyva I, Bortel K, Schalk D, et al. Multidisciplinary care in the oncology setting: historical perspective and data from lung and gynecology multidisciplinary clinics. J Oncol Pract. 2010;6(6):e21–6.CrossRef Horvath LE, Yordan E, Malhotra D, Leyva I, Bortel K, Schalk D, et al. Multidisciplinary care in the oncology setting: historical perspective and data from lung and gynecology multidisciplinary clinics. J Oncol Pract. 2010;6(6):e21–6.CrossRef
20.
go back to reference Onukwugha E, Petrelli NJ, Castro KM, Gardner JF, Jayasekera J, Goloubeva O, et al. ReCAP: impact of multidisciplinary care on processes of cancer care: a multi-institutional study. J Oncol Pract. 2016;12(2):155–6 e7-68.CrossRef Onukwugha E, Petrelli NJ, Castro KM, Gardner JF, Jayasekera J, Goloubeva O, et al. ReCAP: impact of multidisciplinary care on processes of cancer care: a multi-institutional study. J Oncol Pract. 2016;12(2):155–6 e7-68.CrossRef
21.
go back to reference McNair AG, Choh CT, Metcalfe C, Littlejohns D, Barham CP, Hollowood A, et al. Maximising recruitment into randomised controlled trials: the role of multidisciplinary cancer teams. Eur J Cancer. 2008;44(17):2623–6.CrossRef McNair AG, Choh CT, Metcalfe C, Littlejohns D, Barham CP, Hollowood A, et al. Maximising recruitment into randomised controlled trials: the role of multidisciplinary cancer teams. Eur J Cancer. 2008;44(17):2623–6.CrossRef
22.
go back to reference Shore ND, Dinney C, Uzzo R. The Society of Urologic Oncology Clinical Trials Consortium: a brief history and overview. Rev Urol. 2017;19(2):122–4.PubMedPubMedCentral Shore ND, Dinney C, Uzzo R. The Society of Urologic Oncology Clinical Trials Consortium: a brief history and overview. Rev Urol. 2017;19(2):122–4.PubMedPubMedCentral
23.
go back to reference McCray AT, Ide NC. Design and implementation of a national clinical trials registry. J Am Med Inform Assoc. 2000;7(3):313–23.CrossRef McCray AT, Ide NC. Design and implementation of a national clinical trials registry. J Am Med Inform Assoc. 2000;7(3):313–23.CrossRef
24.
go back to reference McCray AT. Better access to information about clinical trials. Ann Intern Med. 2000;133(8):609–14.CrossRef McCray AT. Better access to information about clinical trials. Ann Intern Med. 2000;133(8):609–14.CrossRef
25.
go back to reference Gafford JA, Gurley-Calvez T, Krebill H, Lai SM, Christiadi, Doolittle GC. Expanding local cancer clinical trial options: analysis of the economic impact of the Midwest Cancer Alliance in Kansas. Acad Med. 2017;92(9):1274–9.CrossRef Gafford JA, Gurley-Calvez T, Krebill H, Lai SM, Christiadi, Doolittle GC. Expanding local cancer clinical trial options: analysis of the economic impact of the Midwest Cancer Alliance in Kansas. Acad Med. 2017;92(9):1274–9.CrossRef
26.
go back to reference Ellis SD, Geana M, Mackay CB, Moon DJ, Gills J, Zganjar A, et al. Science in the Heartland: exploring determinants of offering cancer clinical trials in rural-serving community urology practices. Urol Oncol. 2019. Ellis SD, Geana M, Mackay CB, Moon DJ, Gills J, Zganjar A, et al. Science in the Heartland: exploring determinants of offering cancer clinical trials in rural-serving community urology practices. Urol Oncol. 2019.
27.
go back to reference Ellis SD, Geana M, Mackay C, Moon DJ, Gills J, Zganjar A, et al. Science in the Heartland: exploring determinants of offering cancer clinical trials in rural-serving community urology practices. Under review. Ellis SD, Geana M, Mackay C, Moon DJ, Gills J, Zganjar A, et al. Science in the Heartland: exploring determinants of offering cancer clinical trials in rural-serving community urology practices. Under review.
28.
go back to reference American Cancer Society Cancer Action Network. Overcoming barriers to patient enrollment in therapeutic clinical trials for cancer: recommendations. Washington, D.C.: American Cancer Society; 2018. American Cancer Society Cancer Action Network. Overcoming barriers to patient enrollment in therapeutic clinical trials for cancer: recommendations. Washington, D.C.: American Cancer Society; 2018.
29.
go back to reference Lara PN Jr, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001;19(6):1728–33.CrossRef Lara PN Jr, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001;19(6):1728–33.CrossRef
30.
go back to reference Minasian LM, O’Mara AM. Accrual to clinical trials: let’s look at the physicians. J Natl Cancer Inst. 2011;103(5):357–8.CrossRef Minasian LM, O’Mara AM. Accrual to clinical trials: let’s look at the physicians. J Natl Cancer Inst. 2011;103(5):357–8.CrossRef
31.
go back to reference Carpenter WR, Fortune-Greeley AK, Zullig LL, Lee SY, Weiner BJ. Sustainability and performance of the National Cancer Institute’s Community Clinical Oncology Program. Contemp Clin Trials. 2012;33(1):46–54.CrossRef Carpenter WR, Fortune-Greeley AK, Zullig LL, Lee SY, Weiner BJ. Sustainability and performance of the National Cancer Institute’s Community Clinical Oncology Program. Contemp Clin Trials. 2012;33(1):46–54.CrossRef
32.
go back to reference Eggly S, Albrecht TL, Harper FW, Foster T, Franks MM, Ruckdeschel JC. Oncologists’ recommendations of clinical trial participation to patients. Patient Educ Couns. 2008;70(1):143–8.CrossRef Eggly S, Albrecht TL, Harper FW, Foster T, Franks MM, Ruckdeschel JC. Oncologists’ recommendations of clinical trial participation to patients. Patient Educ Couns. 2008;70(1):143–8.CrossRef
33.
go back to reference Kaas R, Hart AA, Rutgers EJ. The impact of the physician on the accrual to randomized clinical trials in patients with primary operable breast cancer. Breast. 2005;14(4):310–6.CrossRef Kaas R, Hart AA, Rutgers EJ. The impact of the physician on the accrual to randomized clinical trials in patients with primary operable breast cancer. Breast. 2005;14(4):310–6.CrossRef
34.
go back to reference Klabunde CN, Keating NL, Potosky AL, Ambs A, He Y, Hornbrook MC, et al. A population-based assessment of specialty physician involvement in cancer clinical trials. J Natl Cancer Inst. 2011;103(5):384–97.CrossRef Klabunde CN, Keating NL, Potosky AL, Ambs A, He Y, Hornbrook MC, et al. A population-based assessment of specialty physician involvement in cancer clinical trials. J Natl Cancer Inst. 2011;103(5):384–97.CrossRef
35.
go back to reference Baer AR, Michaels M, Good MJ, Schapira L. Engaging referring physicians in the clinical trial process. J Oncol Pract. 2012;8(1):e8–e10.CrossRef Baer AR, Michaels M, Good MJ, Schapira L. Engaging referring physicians in the clinical trial process. J Oncol Pract. 2012;8(1):e8–e10.CrossRef
36.
go back to reference Kaplan CP, Napoles AM, Dohan D, Hwang ES, Melisko M, Nickleach D, et al. Clinical trial discussion, referral, and recruitment: physician, patient, and system factors. Cancer Cause Control. 2013;24(5):979–88.CrossRef Kaplan CP, Napoles AM, Dohan D, Hwang ES, Melisko M, Nickleach D, et al. Clinical trial discussion, referral, and recruitment: physician, patient, and system factors. Cancer Cause Control. 2013;24(5):979–88.CrossRef
37.
go back to reference Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7:37.CrossRef Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7:37.CrossRef
38.
go back to reference Dearing JW, Kreuter MW. Designing for diffusion: how can we increase uptake of cancer communication innovations? Patient Educ Couns. 2010;81(Suppl):S100–10.CrossRef Dearing JW, Kreuter MW. Designing for diffusion: how can we increase uptake of cancer communication innovations? Patient Educ Couns. 2010;81(Suppl):S100–10.CrossRef
39.
go back to reference Brownson RC, Jacobs JA, Tabak RG, Hoehner CM, Stamatakis KA. Designing for dissemination among public health researchers: findings from a national survey in the United States. Am J Public Health. 2013;103(9):1693–9.CrossRef Brownson RC, Jacobs JA, Tabak RG, Hoehner CM, Stamatakis KA. Designing for dissemination among public health researchers: findings from a national survey in the United States. Am J Public Health. 2013;103(9):1693–9.CrossRef
40.
go back to reference Medicine UoCDoF. Design for Dissemination Tool. Denver: University of Colorado; 2017. Medicine UoCDoF. Design for Dissemination Tool. Denver: University of Colorado; 2017.
41.
go back to reference Michie S, van Stralen MM, West R. The Behaviour Change Wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42.CrossRef Michie S, van Stralen MM, West R. The Behaviour Change Wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42.CrossRef
42.
go back to reference Michie S, Atkins L, West R. The Behaviour Change Wheel: a guide to designing interventions. Great Britain: Silverback Publishing; 2014. Michie S, Atkins L, West R. The Behaviour Change Wheel: a guide to designing interventions. Great Britain: Silverback Publishing; 2014.
43.
go back to reference Gould GS, Bar-Zeev Y, Bovill M, Atkins L, Gruppetta M, Clarke MJ, et al. Designing an implementation intervention with the Behaviour Change Wheel for health provider smoking cessation care for Australian Indigenous pregnant women. Implement Sci. 2017;12(1):114.CrossRef Gould GS, Bar-Zeev Y, Bovill M, Atkins L, Gruppetta M, Clarke MJ, et al. Designing an implementation intervention with the Behaviour Change Wheel for health provider smoking cessation care for Australian Indigenous pregnant women. Implement Sci. 2017;12(1):114.CrossRef
44.
go back to reference Ellis SD, Thrasher JB, Jones EV, Kimminau KS. Treatment decision making in low-risk prostate cancer: recruitment and data collection feasibility. Sociey for Medical Decision Making Annual Meeting; October, 2015. St. Louis: Society for Annual Decision Making; 2015. Ellis SD, Thrasher JB, Jones EV, Kimminau KS. Treatment decision making in low-risk prostate cancer: recruitment and data collection feasibility. Sociey for Medical Decision Making Annual Meeting; October, 2015. St. Louis: Society for Annual Decision Making; 2015.
45.
go back to reference Ellis SD, Kimminau K, Jones E, Thrasher JB. De-implementing curative therapy in low-risk prostate cancer: preliminary evidence of Urologists’ unlearning. Vancouver, British Columbia: Society for Medical Decision Making Annual Meeting; October 24–26, 2016; 2016. Ellis SD, Kimminau K, Jones E, Thrasher JB. De-implementing curative therapy in low-risk prostate cancer: preliminary evidence of Urologists’ unlearning. Vancouver, British Columbia: Society for Medical Decision Making Annual Meeting; October 24–26, 2016; 2016.
46.
go back to reference Ellis SD, Jones EV, Kimminau K, Petty L, Thrasher JB. Persistent barriers to adoption of active surveillance. Chicago: American Society for Clinical Oncology; 2016.CrossRef Ellis SD, Jones EV, Kimminau K, Petty L, Thrasher JB. Persistent barriers to adoption of active surveillance. Chicago: American Society for Clinical Oncology; 2016.CrossRef
47.
go back to reference Ellis SD, Geana M, Mackay C, Gills J, Griebling T, Zganjar A, et al. When an intervention is not designed for dissemination: developing a strategy to improve system-innovation fit. Arlington: 10th Annual Conference on the Science of Dissemination and Implementation; December 4–6, 2017; 2017. Ellis SD, Geana M, Mackay C, Gills J, Griebling T, Zganjar A, et al. When an intervention is not designed for dissemination: developing a strategy to improve system-innovation fit. Arlington: 10th Annual Conference on the Science of Dissemination and Implementation; December 4–6, 2017; 2017.
48.
go back to reference Brooks JV, Ellis SD, Morrow E, Kimminau KS, Thrasher JB. Patient factors that influence how physicians discuss active surveillance with low-risk prostate cancer patients: a qualitative study. Am J Mens Health. 2018;12(5):1719–27.CrossRef Brooks JV, Ellis SD, Morrow E, Kimminau KS, Thrasher JB. Patient factors that influence how physicians discuss active surveillance with low-risk prostate cancer patients: a qualitative study. Am J Mens Health. 2018;12(5):1719–27.CrossRef
49.
go back to reference Weiner BJ, Lewis CL, Stanick C, Powell BJ, Dorsey CN, Clary AS, et al. Psychometric assessment of three newly developed implementation outcome measures. Under Review. Weiner BJ, Lewis CL, Stanick C, Powell BJ, Dorsey CN, Clary AS, et al. Psychometric assessment of three newly developed implementation outcome measures. Under Review.
50.
go back to reference Logan JK, Tang C, Liao Z, Lee JJ, Heymach JV, Swisher SG, et al. Analysis of factors affecting successful clinical trial enrollment in the context of three prospective, randomized, controlled trials. Int J Radiat Oncol Biol Phys. 2017;97(4):770–7.CrossRef Logan JK, Tang C, Liao Z, Lee JJ, Heymach JV, Swisher SG, et al. Analysis of factors affecting successful clinical trial enrollment in the context of three prospective, randomized, controlled trials. Int J Radiat Oncol Biol Phys. 2017;97(4):770–7.CrossRef
51.
go back to reference Geana M, Erba J. Accrual to Cancer Clinical Trials Project. KU Cancer Center Seminar. Kansas City: KU Cancer Center; 2016. Geana M, Erba J. Accrual to Cancer Clinical Trials Project. KU Cancer Center Seminar. Kansas City: KU Cancer Center; 2016.
52.
go back to reference Hamel LM, Penner LA, Albrecht TL, Heath E, Gwede CK, Eggly S. Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer. Cancer Control. 2016;23(4):327–37.CrossRef Hamel LM, Penner LA, Albrecht TL, Heath E, Gwede CK, Eggly S. Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer. Cancer Control. 2016;23(4):327–37.CrossRef
53.
go back to reference Somkin CP, Ackerson L, Husson G, Gomez V, Kolevska T, Goldstein D, et al. Effect of medical oncologists’ attitudes on accrual to clinical trials in a community setting. J Oncol Pract. 2013;9(6):e275–83.CrossRef Somkin CP, Ackerson L, Husson G, Gomez V, Kolevska T, Goldstein D, et al. Effect of medical oncologists’ attitudes on accrual to clinical trials in a community setting. J Oncol Pract. 2013;9(6):e275–83.CrossRef
54.
go back to reference Leitch AM, Beitsch PD, McCall LM, Posther K, Newman LA, Herndon JE 2nd, et al. Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. Am J Surg. 2005;190(4):539–42.CrossRef Leitch AM, Beitsch PD, McCall LM, Posther K, Newman LA, Herndon JE 2nd, et al. Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. Am J Surg. 2005;190(4):539–42.CrossRef
55.
go back to reference Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, et al. RE-AIM Planning and Evaluation Framework: adapting to new science and practice with a 20-year review. Front Public Health. 2019;7:64.CrossRef Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, et al. RE-AIM Planning and Evaluation Framework: adapting to new science and practice with a 20-year review. Front Public Health. 2019;7:64.CrossRef
56.
go back to reference Lee SJC, Murphy CC, Geiger AM, Gerber DE, Cox JV, Nair R, et al. Conceptual model for accrual to cancer clinical trials. J Clin Oncol. 2019; JCO1900101. Lee SJC, Murphy CC, Geiger AM, Gerber DE, Cox JV, Nair R, et al. Conceptual model for accrual to cancer clinical trials. J Clin Oncol. 2019; JCO1900101.
57.
go back to reference Ersek JL, Black LJ, Thompson MA, Kim ES. Implementing precision medicine programs and clinical trials in the community-based oncology practice: barriers and best practices. Am Soc Clin Oncol Educ Book. 2018;38:188–96.CrossRef Ersek JL, Black LJ, Thompson MA, Kim ES. Implementing precision medicine programs and clinical trials in the community-based oncology practice: barriers and best practices. Am Soc Clin Oncol Educ Book. 2018;38:188–96.CrossRef
58.
go back to reference Unger JM, Moseley A, Symington B, Chavez-MacGregor M, Ramsey SD, Hershman DL. Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials. JAMA Netw Open. 2018:1(4):e181235.CrossRef Unger JM, Moseley A, Symington B, Chavez-MacGregor M, Ramsey SD, Hershman DL. Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials. JAMA Netw Open. 2018:1(4):e181235.CrossRef
59.
go back to reference Carlos RC, Sicks JD, Chang GJ, Lyss AP, Stewart TL, Sung L, et al. Capacity for cancer care delivery research in National Cancer Institute Community Oncology Research Program Community Practices: availability of radiology and primary care research partners. J Am Coll Radiol. 2017;14(12):1530–7.CrossRef Carlos RC, Sicks JD, Chang GJ, Lyss AP, Stewart TL, Sung L, et al. Capacity for cancer care delivery research in National Cancer Institute Community Oncology Research Program Community Practices: availability of radiology and primary care research partners. J Am Coll Radiol. 2017;14(12):1530–7.CrossRef
60.
go back to reference Urology Care Foundation. In: Association AU, editor. Clinical Trials Fact Sheet. Linthicum: American Urological Association; 2018. Urology Care Foundation. In: Association AU, editor. Clinical Trials Fact Sheet. Linthicum: American Urological Association; 2018.
61.
go back to reference Blanke CD. In: Network SCR, editor. The Front Line. Seattle: SWOG Cancer Research Network; 2018. Blanke CD. In: Network SCR, editor. The Front Line. Seattle: SWOG Cancer Research Network; 2018.
62.
go back to reference Nipp RD, Hong K, Paskett ED. Overcoming barriers to clinical trial enrollment. Am Soc Clin Oncol Educ Book. 2019;39:105–14.CrossRef Nipp RD, Hong K, Paskett ED. Overcoming barriers to clinical trial enrollment. Am Soc Clin Oncol Educ Book. 2019;39:105–14.CrossRef
63.
go back to reference Geana M, Erba J, Krebill H, Doolittle G, Madhusudhana S, Qasem A, et al. Searching for cures: inner-city and rural patients’ awareness and perceptions of cancer clinical trials. Contemp Clin Trials Commun. 2017;5:72–9.CrossRef Geana M, Erba J, Krebill H, Doolittle G, Madhusudhana S, Qasem A, et al. Searching for cures: inner-city and rural patients’ awareness and perceptions of cancer clinical trials. Contemp Clin Trials Commun. 2017;5:72–9.CrossRef
64.
go back to reference Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, et al. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017;12(1):108.CrossRef Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, et al. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017;12(1):108.CrossRef
65.
go back to reference Kaluzny AD, Lacey LM, Warnecke R, Morrissey JP, Sondik EJ, Ford L. Accrual of patients to randomized clinical trials. Factors affecting cancer prevention and control research. Int J Technol Assess Health Care. 1994;10(3):506–16.CrossRef Kaluzny AD, Lacey LM, Warnecke R, Morrissey JP, Sondik EJ, Ford L. Accrual of patients to randomized clinical trials. Factors affecting cancer prevention and control research. Int J Technol Assess Health Care. 1994;10(3):506–16.CrossRef
66.
go back to reference Waltz TJ, Powell BJ, Fernandez ME, Abadie B, Damschroder LJ. Choosing implementation strategies to address contextual barriers: diversity in recommendations and future directions. Implement Sci. 2019;14(1):42.CrossRef Waltz TJ, Powell BJ, Fernandez ME, Abadie B, Damschroder LJ. Choosing implementation strategies to address contextual barriers: diversity in recommendations and future directions. Implement Sci. 2019;14(1):42.CrossRef
67.
go back to reference Kitterman DR, Cheng SK, Dilts DM, Orwoll ES. The prevalence and economic impact of low-enrolling clinical studies at an academic medical center. Acad Med. 2011;86(11):1360–6.CrossRef Kitterman DR, Cheng SK, Dilts DM, Orwoll ES. The prevalence and economic impact of low-enrolling clinical studies at an academic medical center. Acad Med. 2011;86(11):1360–6.CrossRef
Metadata
Title
Development, acceptability, appropriateness and appeal of a cancer clinical trials implementation intervention for rural- and minority-serving urology practices
Authors
Shellie Ellis
Mugur Geana
Tomas Griebling
Charles McWilliams
Jessie Gills
Kelly Stratton
Christine Mackay
Ariel Shifter
Andrew Zganjar
Brantley Thrasher
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Care
Published in
Trials / Issue 1/2019
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-019-3658-z

Other articles of this Issue 1/2019

Trials 1/2019 Go to the issue